Phase 2 N=183 Randomized Double-blind Treatment

Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease

Dry Eye Disease

Bottom Line

View on ClinicalTrials.gov: NCT00667004 ↗

Enrolled (actual)

183

Serious AEs

0.5%

Results posted

Sep 2020

Primary outcome: Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: ecabet ophthalmic solution (Drug); placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Bausch & Lomb Incorporated
Primary completion: Sep 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test	3.02; 2.15; 2.35; 1.35	—

Summary

Efficacy study of ecabet ophthalmic solution in dry eye disease

Eligibility Criteria

Inclusion Criteria

Diagnosed with dry eye disease

Exclusion Criteria

Dry eye disease secondary to surgery

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00667004). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.